PGC1α and VDAC1 expression in endometrial cancer

Castro Wersäll,Ofra; Löfstedt,Lina; Govorov,Igor; Mints,Miriam; Gabrielson,Marike; Shoshan,Maria

doi:10.3892/mco.2020.2203

PGC1α and VDAC1 expression in endometrial cancer

Authors:
- Ofra Castro Wersäll
- Lina Löfstedt
- Igor Govorov
- Miriam Mints
- Marike Gabrielson
- Maria Shoshan
View Affiliations

Affiliations: Division of Obstetrics and Gynecology, Department of Women's and Children's Health, Karolinska Institute, Stockholm 171 77, Sweden, Department of Oncology‑Pathology, BioClinicum, Karolinska Institute, Solna 171 64, Sweden
Published online on: December 30, 2020 https://doi.org/10.3892/mco.2020.2203
Article Number: 42

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Endometrial cancer (EC) is one of the ten most common gynecological cancers. As in most cancers, EC tumour progression involves alterations in cellular metabolism and can be associated with, for instance, altered levels of glycolytic enzymes. Mitochondrial functions and proteins are known to serve key roles in tumour metabolism and progression. The transcriptional coactivator peroxisome proliferator‑activated receptor gamma coactivator 1 (PGC1α) is a major regulator of mitochondrial biogenesis and function, albeit of varying prognostic value in different cancers. The voltage‑dependent anion channel type 1 (VDAC1) regulates apoptosis as well as metabolite import and export over the mitochondrial outer membrane, and is often used for comparative quantification of mitochondrial content. Using immunohistochemistry, the present study examined protein expression levels of PGC1α and VDAC1 in tumour and paired benign tissue samples from 148 patients with EC, in order to examine associations with clinical data, such as stage and grade, Ki‑67, p53 status, clinical resistance and overall survival. The expression levels of both PGC1α and VDAC1, as well as a PGC1α downstream effector, were significantly lower in tumor tissues than in benign tissues, suggesting altered mitochondrial function in EC. However, Kaplan‑Meier, log rank and Spearman's rank correlation tests revealed that their expression was not correlated with survival and clinical data. Therefore, PGC1α and VDAC1 are not of major prognostic value in EC.

View Figures

View References

1	Arora V and Quinn MA: Endometrial cancer. Best Pract Res Clin Obstet Gynaecol. 26:311–324. 2012.PubMed/NCBI View Article : Google Scholar
2	Harris HR and Terry KL: Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: A systematic review. Fertil Res Pract. 2(14)2016.PubMed/NCBI View Article : Google Scholar
3	Raglan O, Kalliala I, Markozannes G, Cividini S, Gunter MJ, Nautiyal J, Gabra H, Paraskevaidis E, Martin-Hirsch P, Tsilidis KK and Kyrgiou M: Risk factors for endometrial cancer: An umbrella review of the literature. Int J Cancer. 145:1719–1730. 2019.PubMed/NCBI View Article : Google Scholar
4	Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C and Sessa C: ESMO Guidelines Working Group. Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24 (Suppl 6):vi35–vi39. 2011.PubMed/NCBI View Article : Google Scholar
5	Yeramian A, Moreno-Bueno G, Dolcet X, Catasus L, Abal M, Colas E, Reventos J, Palacios J, Prat J and Matias-Guiu X: Endometrial carcinoma: Molecular alterations involved in tumor development and progression. Oncogene. 32:403–413. 2013.PubMed/NCBI View Article : Google Scholar
6	Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E and Vergote I: Endometrial cancer. Lancet. 366:491–505. 2005.PubMed/NCBI View Article : Google Scholar
7	Porporato PE, Payen VL, Baselet B and Sonveaux P: Metabolic changes associated with tumor metastasis, part 2: Mitochondria, lipid and amino acid metabolism. Cell Mol Life Sci. 73:1349–1363. 2016.PubMed/NCBI View Article : Google Scholar
8	DeBerardinis RJ and Chandel NS: Fundamentals of cancer metabolism. Sci Adv. 2(e1600200)2016.PubMed/NCBI View Article : Google Scholar
9	Hjerpe E, Egyhazi Brage S, Carlson J, Frostvik Stolt M, Schedvins K, Johansson H, Shoshan M and Avall-Lundqvist E: Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer. BMC Clin Pathol. 13(30)2013.PubMed/NCBI View Article : Google Scholar
10	Guaragnella N, Giannattasio S and Moro L: Mitochondrial dysfunction in cancer chemoresistance. Biochem Pharmacol. 92:62–72. 2014.PubMed/NCBI View Article : Google Scholar
11	Guerra F, Arbini AA and Moro L: Mitochondria and cancer chemoresistance. Biochim Biophys Acta Bioenerg. 1858:686–699. 2017.PubMed/NCBI View Article : Google Scholar
12	Porporato PE, Payen VL, Perez-Escuredo J, De Saedeleer CJ, Danhier P, Copetti T, Dhup S, Tardy M, Vazeille T, Bouzin C, et al: A mitochondrial switch promotes tumor metastasis. Cell Rep. 8:754–766. 2014.PubMed/NCBI View Article : Google Scholar
13	Villena JA: New insights into PGC-1 coactivators: Redefining their role in the regulation of mitochondrial function and beyond. FEBS J. 282:647–672. 2015.PubMed/NCBI View Article : Google Scholar
14	Gabrielson M, Bjorklund M, Carlson J and Shoshan M: Expression of mitochondrial regulators PGC1α and TFAM as putative markers of subtype and chemoresistance in epithelial ovarian carcinoma. PLoS One. 9(e107109)2014.PubMed/NCBI View Article : Google Scholar
15	Guerra F, Kurelac I, Cormio A, Zuntini R, Amato LB, Ceccarelli C, Santini D, Cormio G, Fracasso F, Selvaggi L, et al: Placing mitochondrial DNA mutations within the progression model of type I endometrial carcinoma. Hum Mol Genet. 20:2394–2405. 2011.PubMed/NCBI View Article : Google Scholar
16	Cormio A, Guerra F, Cormio G, Pesce V, Fracasso F, Loizzi V, Cantatore P, Selvaggi L and Gadaleta MN: The PGC-1alpha-dependent pathway of mitochondrial biogenesis is upregulated in type I endometrial cancer. Biochem Biophys Res Commun. 390:1182–1185. 2009.PubMed/NCBI View Article : Google Scholar
17	Mastropasqua F, Girolimetti G and Shoshan M: PGC1α: Friend or Foe in. cancer? Genes (Basel). 9(48)2018.PubMed/NCBI View Article : Google Scholar
18	Shoshan-Barmatz V and De S: Mitochondrial VDAC, the Na⁺/Ca²⁺ Exchanger, and the Ca²⁺ Uniporter in Ca²⁺ dynamics and signaling. Adv Exp Med Biol. 981:323–347. 2017.PubMed/NCBI View Article : Google Scholar
19	Shoshan-Barmatz V and Mizrachi D: VDAC1: From structure to cancer therapy. Front Oncol. 2(164)2012.PubMed/NCBI View Article : Google Scholar
20	Shoshan-Barmatz V and Ben-Hail D: VDAC, a multi-functional mitochondrial protein as a pharmacological target. Mitochondrion. 12:24–34. 2012.PubMed/NCBI View Article : Google Scholar
21	Li LT, Jiang G, Chen Q and Zheng JN: Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep. 11:1566–1572. 2015.PubMed/NCBI View Article : Google Scholar
22	Teicher BA, Linehan WM and Helman LJ: Targeting cancer metabolism. Clin Cancer Res. 18:5537–5545. 2012.PubMed/NCBI View Article : Google Scholar
23	Salvesen HB, Iversen OE and Akslen LA: Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin Cancer Res. 4:2779–2785. 1998.PubMed/NCBI
24	Cormio A, Cormio G, Musicco C, Sardanelli AM, Gasparre G and Gadaleta MN: Mitochondrial changes in endometrial carcinoma: Possible role in tumor diagnosis and prognosis (review). Oncol Rep. 33:1011–1018. 2015.PubMed/NCBI View Article : Google Scholar
25	Ren Z, Yang H, Wang C and Ma X: The effects of PGC-1α on the proliferation and energy metabolism of malignant endometrial cancer cells. Onco Targets Ther. 8:769–774. 2015.PubMed/NCBI View Article : Google Scholar
26	Feilchenfeldt J, Brundler MA, Soravia C, Totsch M and Meier CA: Peroxisome proliferator-activated receptors (PPARs) and associated transcription factors in colon cancer: Reduced expression of PPARgamma-coactivator 1 (PGC-1). Cancer Lett. 203:25–33. 2004.PubMed/NCBI View Article : Google Scholar
27	Watkins G, Douglas-Jones A, Mansel RE and Jiang WG: The localisation and reduction of nuclear staining of PPARgamma and PGC-1 in human breast cancer. Oncol Rep. 12:483–488. 2004.PubMed/NCBI
28	Luo C, Lim JH, Lee Y, Granter SR, Thomas A, Vazquez F, Widlund HR and Puigserver P: A PGC1α-mediated transcriptional axis suppresses melanoma metastasis. Nature. 537:422–426. 2016.PubMed/NCBI View Article : Google Scholar
29	Shoshan-Barmatz V, Ben-Hail D, Admoni L, Krelin Y and Tripathi SS: The mitochondrial voltage-dependent anion channel 1 in tumor cells. Biochim Biophys Acta. 1848:2547–2575. 2015.PubMed/NCBI View Article : Google Scholar